Informations générales (source: ClinicalTrials.gov)
Research on Severe Asthma
Observational
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
septembre 2019
septembre 2025
14 septembre 2025
The French Society for Respiratory diseases (SPLF), through its Asthma and Allergy
working group (G2A), wishes to set up a national cohort of severe asthma patients to
describe this population and the use of step 4 and 5 treatment. This study also meets the
demand for post - registration studies required by the Health Authorities for
biotherapies and bronchial thermoplasty.
Other European or international cohorts of asthmatic patients exist and RAMSES could
contribute to data sharing initiatives.
Etablissements
Critères
Tous
Inclusion Criteria:
- Patient with severe asthma : Meeting the definition of ATS-ERS: which requires a
combination of high dose CSI and B2LDA.
Or receiving level 5 support (initiating treatment or already treated) :
- Long-term oral corticosteroids (> 6 months in the year prior to inclusion)
- And / or monoclonal antibody
- And / or bronchial thermoplasty
- And / or other complex costs corresponding to the level 5 treatments
- Consultant or hospitalized in one of the centers participating in RAMSES study
- Patient with severe asthma : Meeting the definition of ATS-ERS: which requires a
combination of high dose CSI and B2LDA.
Or receiving level 5 support (initiating treatment or already treated) :
- Long-term oral corticosteroids (> 6 months in the year prior to inclusion)
- And / or monoclonal antibody
- And / or bronchial thermoplasty
- And / or other complex costs corresponding to the level 5 treatments
- Consultant or hospitalized in one of the centers participating in RAMSES study
- Patient does not accept the recording of his data in the cohort
- Patient not benefiting from health insurance coverage
- Patient under curatorship or tutorship